Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

At just 29 years old, the Queensland mum has been diagnosed with a rare hereditary form of Alzheimer’s disease. It is the ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.